[go: up one dir, main page]

SV2006002100A - Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos ref. p-sv-78.159/msu - Google Patents

Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos ref. p-sv-78.159/msu

Info

Publication number
SV2006002100A
SV2006002100A SV2005002100A SV2005002100A SV2006002100A SV 2006002100 A SV2006002100 A SV 2006002100A SV 2005002100 A SV2005002100 A SV 2005002100A SV 2005002100 A SV2005002100 A SV 2005002100A SV 2006002100 A SV2006002100 A SV 2006002100A
Authority
SV
El Salvador
Prior art keywords
hemorragy
msu
disruption
ref
treatment
Prior art date
Application number
SV2005002100A
Other languages
English (en)
Inventor
Andreas Sachse
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35056905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2006002100(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of SV2006002100A publication Critical patent/SV2006002100A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

USO DE UN REGIMEN EXTENDIDO FLEXIBLE PARA LA ANTICONCEPCION HORMONAL, UTIL PARA TRATAR PROBLEMAS DE HEMORRAGIAS ASOCIADOS CON EL USO EXTENDIDO FIJO DE ANTICONCEPTIVOS HORMONALES Y ENVASE FARMACEUTICO QUE CONTIENE EL RESPECTIVO ANTICONCEPTIVO HORMONAL
SV2005002100A 2004-04-30 2005-04-29 Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos ref. p-sv-78.159/msu SV2006002100A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US56644304P 2004-04-30 2004-04-30
US57502404P 2004-05-28 2004-05-28
US57719904P 2004-06-07 2004-06-07
US63838004P 2004-12-27 2004-12-27
US66006805P 2005-03-10 2005-03-10

Publications (1)

Publication Number Publication Date
SV2006002100A true SV2006002100A (es) 2006-02-15

Family

ID=35056905

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2005002100A SV2006002100A (es) 2004-04-30 2005-04-29 Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos ref. p-sv-78.159/msu

Country Status (29)

Country Link
US (3) US8163721B2 (es)
EP (1) EP1747001B1 (es)
JP (4) JP2007535519A (es)
KR (4) KR20130022425A (es)
CN (1) CN103127156A (es)
AR (1) AR048722A1 (es)
AU (1) AU2005237255B2 (es)
BR (1) BRPI0510493A (es)
CA (1) CA2562296A1 (es)
CR (1) CR8709A (es)
DK (1) DK1747001T3 (es)
EA (2) EA016625B1 (es)
EC (1) ECSP066999A (es)
ES (1) ES2704999T3 (es)
HU (1) HUE041475T2 (es)
IL (1) IL178458A (es)
LT (1) LT1747001T (es)
MX (1) MXPA06012567A (es)
MY (1) MY151322A (es)
NO (1) NO341685B1 (es)
NZ (1) NZ586107A (es)
PA (1) PA8631801A1 (es)
PE (1) PE20060467A1 (es)
SG (2) SG152288A1 (es)
SI (1) SI1747001T1 (es)
SV (1) SV2006002100A (es)
TW (1) TWI374735B (es)
UY (1) UY28875A1 (es)
WO (1) WO2005105103A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US20070088010A1 (en) * 2005-10-17 2007-04-19 Doris Huebler Method of making a single-stage pharmaceutical preparation for oral therapy of dysfunctional uterine bleeding, containing ethinyl estradiol and dienogest
EP1977752A1 (de) * 2007-03-01 2008-10-08 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zubereitung zur Verminderung der Endometriose
DE102007011105A1 (de) * 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
WO2010033188A2 (en) * 2008-09-16 2010-03-25 Playtex Products, Llc. Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administering same
WO2010042610A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
EP2343979B1 (en) 2008-10-08 2020-04-08 Agile Therapeutics, Inc. Transdermal delivery
WO2010042607A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc Transdermal delivery
EP2410859A4 (en) 2009-03-27 2013-03-13 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
CN107810001A (zh) 2015-06-18 2018-03-16 密特拉制药公司 含雌四醇的口腔分散片剂
PL3106148T3 (pl) 2015-06-18 2018-08-31 Mithra Pharmaceuticals S A Jednostka dawkowania ulegająca rozpadowi w jamie ustnej zawierająca składnik estetrolowy
CN107787224A (zh) 2015-06-18 2018-03-09 密特拉制药公司 含雌四醇组分的口腔分散剂量单位
CA2988362C (en) 2015-06-18 2022-07-19 Mithra Pharmaceuticals S.A. Orodispersible tablet containing estetrol
CA2989975C (en) * 2015-06-23 2021-10-12 Laboratorios Leon Farma Sa Drospirenone-based contraceptive for a female patient affected with excess weight
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
SMT202200254T1 (it) 2016-09-30 2022-07-21 Takeda Pharmaceuticals Co Metodi di trattamento di fibromi uterini ed endometriosi
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
US12138270B2 (en) 2021-09-07 2024-11-12 Millicent Pharma Limited Contraceptive regimen including reduced level of estrogen

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244096A (en) * 1988-04-22 1993-09-14 Stoner Fred L Preventive treatment kit against sexually transmitted disease
AU3473193A (en) 1992-01-17 1993-08-03 Procter & Gamble Company, The Treatment for atherosclerosis
DE4344462C2 (de) 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
US5552394A (en) * 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
ES2223081T3 (es) 1996-07-26 2005-02-16 Wyeth Metodo anticonceptivo oral monofasico y kit que comprende una combinacion de progestina y estrogeno.
US6451778B1 (en) * 1996-07-26 2002-09-17 Wyeth Oral contraceptive
US5842441A (en) 1996-08-26 1998-12-01 Pharmalett Denmark A/S Medicated and individualized treatment shampoo for dermatological disturbances of companion animals
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
KR101019361B1 (ko) 1999-08-31 2011-03-07 바이엘 쉐링 파마 악티엔게젤샤프트 피임약으로서의 사용을 위한 에티닐에스트라디올과드로스피렌온의 약학적 조합
CO5271709A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
US6653298B2 (en) * 2000-01-14 2003-11-25 Sterix Limited Composition
DE10045380A1 (de) * 2000-09-14 2002-04-04 Schering Ag Verfahren zur Kontrazeption und dessen Darreichungsform
IL145876A0 (en) * 2000-10-17 2002-07-25 Pfizer Prod Inc Methods and kits for improving vascular health
US20020193356A1 (en) * 2001-05-23 2002-12-19 Van Beek Agatha Antonia Magdalena Means and method for hormonal contraception
US20030018018A1 (en) 2001-07-10 2003-01-23 Medical College Of Hampton Roads Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
US8501720B2 (en) * 2004-07-30 2013-08-06 Bayer Pharma AG Method for treatment of dysmenorrhea

Also Published As

Publication number Publication date
JP2007535519A (ja) 2007-12-06
AU2005237255A1 (en) 2005-11-10
IL178458A0 (en) 2008-04-13
NO341685B1 (no) 2017-12-18
SI1747001T1 (sl) 2019-02-28
AU2005237255B2 (en) 2011-07-07
HUE041475T2 (hu) 2019-05-28
JP2015187157A (ja) 2015-10-29
ES2704999T3 (es) 2019-03-21
WO2005105103A3 (en) 2006-09-08
NO20065499L (no) 2006-11-29
KR20160150113A (ko) 2016-12-28
JP6134491B2 (ja) 2017-05-24
CR8709A (es) 2007-08-28
EA031227B1 (ru) 2018-12-28
NZ586107A (en) 2012-05-25
US20050250747A1 (en) 2005-11-10
KR20130022425A (ko) 2013-03-06
CA2562296A1 (en) 2005-11-10
EA200601908A1 (ru) 2007-04-27
AR048722A1 (es) 2006-05-17
EA201200377A1 (ru) 2012-08-30
KR20150058555A (ko) 2015-05-28
DK1747001T3 (en) 2019-02-04
IL178458A (en) 2016-08-31
TW200603781A (en) 2006-02-01
EP1747001B1 (en) 2018-10-10
EA016625B1 (ru) 2012-06-29
JP2013018787A (ja) 2013-01-31
PA8631801A1 (es) 2006-11-09
KR101812160B1 (ko) 2017-12-27
JP2017048253A (ja) 2017-03-09
SG152288A1 (en) 2009-05-29
US8163721B2 (en) 2012-04-24
PE20060467A1 (es) 2006-06-11
KR20070004919A (ko) 2007-01-09
JP6153967B2 (ja) 2017-06-28
EA201200377A8 (ru) 2018-01-31
US20150174142A1 (en) 2015-06-25
UY28875A1 (es) 2005-11-30
MY151322A (en) 2014-05-15
WO2005105103A2 (en) 2005-11-10
US20120202779A1 (en) 2012-08-09
LT1747001T (lt) 2019-01-25
TWI374735B (en) 2012-10-21
ECSP066999A (es) 2006-12-29
SG10201701904TA (en) 2017-05-30
MXPA06012567A (es) 2006-12-15
BRPI0510493A (pt) 2007-11-13
CN103127156A (zh) 2013-06-05
EP1747001A2 (en) 2007-01-31

Similar Documents

Publication Publication Date Title
SV2006002100A (es) Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos ref. p-sv-78.159/msu
CY1120879T1 (el) Πολλαπλου συστατικου βιοδραστικος ενδοκολπικος δακτυλιος
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
CL2008001268A1 (es) Compuestos derivados de n-[6-amino-5-aril-piridin-2-il]-carboxamida; composicion farmaceutica que los comprende; composicion farmaceutica combinada que los comprende junto a otro agente farmacologico adicional; y uso de los mismos en el tratamiento del dolor.
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
ECSP088097A (es) Nuevos regímenes para dispositivos de administración controlada de fármacos para anticoncepción
UY28933A1 (es) Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos
CL2007003523A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
BR0309544A (pt) Preparação farmacêutica contendo oxicodona e naloxona
ECSP003847A (es) Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco
UY27720A1 (es) Aroilpiridinonas monocíclicas,
AR052774A1 (es) Inmunoterapia para trastornos autoinmunes
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
BR112013010829B8 (pt) Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação
PE20081881A1 (es) Agentes terapeuticos para canceres resistentes a agentes quimioterapicos que incluyen como ingrediente activo un anticuerpo que reconoce hla de clase i y sus usos
BRPI0511420A (pt) fosforodiamidatos de sulfoniletila
BR112012014159A2 (pt) Combinações terapêuticas de teobromina e um anti-histamínico
MX2007004025A (es) Uso de derivados del acido nordihidroguaiaretico en el tratamiento de cancer e infecciones microbial y viral resistente a farmacos._.
HRP20080569T3 (en) Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin
NO20091628L (no) Kombinasjonsmedikament
TW200642682A (en) A combination of medical drugs to augment the anti-cancer effect of chemotherapy
AR030140A1 (es) Composiciones derivadas de la 2-piridinamina y metodos relacionados
AR023597A1 (es) Utilizacion del saredutant y de sus sales farmaceuticamente aceptables para la preparacion de medicamentos utiles en el tratamiento o la prevencion delconjunto de los trastornos del humor, de los trastornos de adaptacion o de los trastornos mixtos ansiedad-depresion
BRPI0507463A (pt) uso de glufosfamide e gemcitabine , produto, e, combinação de glufosfamide e gemcitabine
CL2010001594A1 (es) Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida.